Skip to main
AUTL

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics is poised for success with their innovative T cell programming technologies and a strong product pipeline for addressing a range of diseases. The company's positive financial results and growth into new markets, as well as promising data from clinical trials, make it a compelling investment opportunity for those with a long-term outlook. However, risks must be considered, such as potential competition and the challenges of successfully bringing new therapies to market.

Bears say

Autolus Therapeutics is facing challenges in attracting investors due to competition in the market, potential side effects of their therapies, and high development costs. While Autolus Therapeutics has reported strong earnings and progress in launching their CAR-T therapy, Aucatzyl, for B-ALL, their slightly lower earnings in the first quarter and potential side effects of their therapies may raise concerns for investors. The company is expected to see growth in authorized treatment centers and additional expansion in the UK, but competition in the market and high development costs pose challenges for the company's future success. Additionally, the use of the 4-1BB co-stimulatory domain in their therapies may provide a unique safety and efficacy profile, but their ongoing efforts to increase manufacturing capacity and improve processes are crucial for their success in the highly competitive biopharmaceutical industry.

Autolus Therapeutics (AUTL) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Buy based on their latest research and market trends.

According to 4 analysts, Autolus Therapeutics (AUTL) has a Buy consensus rating as of Jun 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.